OUTLINE
=======

Plant lectins have attracted much attention for biomedical applications, especially due to their remarkable anti-tumor properties, resulting from their ability to induce programmed cell death and/or autophagocytosis in cancer cells ([@B22]; [@B13]). Plant lectins are also relevant for biomedical diagnosis ([@B24]).

Frutalin is a plant lectin with reported immunomodulatory ([@B3], [@B4]), anti-tumor ([@B31]), and tumor biomarker ([@B33]) properties, among other capacities ([@B10]), and is a good example of how recombinant production of plant lectins can be challenging but also advantageous for obtaining bioactive derivatives for biomedical application. Frutalin is found in extracts of *Artocarpus incisa* (breadfruit) seeds ([@B34]), from which it can be purified by affinity chromatography on cross-linked *Adenanthera pavonina* galactomannan ([@B25]). The name "frutalin" (hereinafter referred to as FTL) is a composite of part of the Portuguese common name of the lectin source plant ("fruta" of "fruta-pão") followed by the suffix "-lin". Although having sugar-binding preference toward [D]{.smallcaps}-galactose, FTL presents a rather broad sugar-binding activity, interacting also with other sugars, as [D]{.smallcaps}-mannose and [D]{.smallcaps}-glucose. FTL belongs to the jacalin-related lectins family (JRLs, found in the Moraceae plant family), specifically to the sub-family of the galactose-specific lectins (gJRLs), as it presents high structural homology, sugar specificity and sequential identity with jacalin (the galactose-specific lectin of *Artocarpus integrifolia* seeds -- jackfruit, the first member of this family to be identified; [@B34]; [@B25]; [@B29]). FTL is characterized by a strong and identical agglutinating activity with human erythrocytes of the ABO system and rabbit erythrocytes, which has no requirements for divalent metal cations ([@B25]). Interestingly, the hemagglutination activity (HA) of FTL is three times higher than that of jacalin ([@B26]). FTL has a sophisticated processing. The conversion of the primary translation product of gJRL-mRNA into the protein includes a complex series of co- and post-translational modifications including the removal of the signal peptide (vacuolar targeting), a (partial) glycosylation, removal of the *N*-terminal propeptide, the excision of a linker tetrapeptide, to separate two polypeptide chains (α and β), proper folding and oligomer assembly. Molecular cloning of the FTL cDNA (excluding signal and propeptide), revealed that, as jacalin, it may be encoded by a family of genes, each of them containing 471 bp, corresponding to a protein of 157 amino-acids, with a calculated molecular weight of 17.1 kDa ([@B29]). Twenty amino-acids correspond to the β-chain, 4 amino-acids to the linker "T-S-S-N" and 133 amino-acids correspond to the α-chain (from *N*- to *C*-terminal). Several gJRLs conserved regions of amino-acids were found in FTL sequences, including the linker. The linker, and its processing, is specific for the sub-group of the gJRLs, being absent in the other sub-group (mannose-specific JRLs; [@B16]). FTL is a heterogeneous mixture of several slightly different amino-acid sequences sharing 93--97% of identity, with or without consensus sequences for *N*-glycosylation (Asn-X-Thr/Ser) in the α-chain (one of these potential *N*-glycosylation sites was also reported for jacalin; [@B29]). In fact, FTL is a partly glycosylated protein, with 2.1% of carbohydrates ([@B25]). Different FTL isoforms or iso-lectins (i.e., different mature sequences) may have distinct biological activities, as reported for other plant lectins ([@B35]; [@B28]). Under denaturing conditions (SDS-PAGE), FTL presents two bands: the upper band (15.5 kDa) corresponds to the highly glycosylated isoforms of α chain, whereas the lower band (12 kDa) represents the slightly or non-glycosylated isoforms of the same chain ([@B30]). The β chain is not visible due to its low molecular weight (2.1 kDa; [@B30]). In its native form, FTL is a tetrameric molecule, consisting of four monomers bound by non-covalent linkages, each containing one β and one α chain, forming four sugar-binding sites, with a predominantly β sheet conformation ([@B25]; [@B5]) and an apparent molecular mass of 48--49 kDa ([@B25]; [@B30]). FTL is a robust protein as it is stable up to 60°C and very resistant to chemical denaturation ([@B5]).

Plant lectins are commonly isolated from their natural sources, although this presents several disadvantages, as the resulting isoforms. Recombinant production, mainly in microbial hosts, is an interesting way to overcome this problem, whilst it may allow to improve availability, ensure continuous supply and facilitate purification of lectins with interesting activities or improved/tailor-made functionalities, particularly for biomedical application (for a recent review see [@B32]).

This review describes the case study of the different strategies applied for the production of FTL in the bacterium *Escherichia coli* ([@B29]; [@B6]; [@B8]) and in the yeast *Pichia pastoris* ([@B30]). Several variables were considered for optimization: codon usage, strains, fusion partners, induction conditions, and purification methodology. Both microorganisms are well-established platforms for the production of recombinant proteins, including several approved biopharmaceutical products ([@B2]; [@B15]). These are also the most employed hosts for the production of recombinant lectins, namely plant lectins for biomedical purposes, such as jacalin ([@B37], [@B36]), aviscumin (from *Viscum album*; [@B41]), PCL (from *Polygonatum cyrtonema*; [@B20]), Orysata (from *Oryza sativa*; [@B1]), and GNA~maize~ (from *Galanthus nivalis*; [@B11]). *E. coli* is commonly used to produce non-glycosylated lectins, while *P. pastoris* is mainly employed to overcome problems of insoluble expression of the bacterial system and to produce glycosylated lectins. Thus, *E. coli* and *P. pastoris* were chosen to produce non-glycosylated recombinant frutalin (EcrFTL) and glycosylated recombinant frutalin (PprFTL), respectively. The bio-molecular characterization of the recombinant FTL obtained from each host in terms of processing, molecular weight, HA and sugar-binding activity is herein presented. Finally, a main focus is given to PprFTL due to its demonstrated anti-tumor and tumor biomarker activities ([@B33], [@B31]).

PRODUCTION OF RECOMBINANT FRUTALIN IN *E. coli*
===============================================

A FTL cDNA sequence was used for production of recombinant FTL in *E. coli* by different strategies ([@B29]). The first attempts to produce soluble EcrFTL in *E. coli* focused in the use of engineered *E. coli* strains that have extra copies of rare tRNAs and in the optimization of the induction conditions, but resulted in low yields ([@B29]; [@B6]). The soluble production of EcrFTL from strain *E. coli* BL21 Codon Plus RIPL (DE3), harboring the pET-25b(+) expression vector (Novagen), was maximized to 16 mg/l by the implementation of an experimental factorial design ([@B29]; **Figure [1](#F1){ref-type="fig"}**). However, all the experimental conditions resulted in EcrFTL produced predominantly as insoluble protein. Even though, EcrFTL was purified from crude *E. coli* extracts by sequential size exclusion (SEC) and cation ion exchange chromatography (IEC) that yielded 76 μg of protein per liter of *E. coli* culture. Purified EcrFTL migrated in SDS-PAGE gel as a homogeneous single-band protein with a molecular mass of about 17 kDa, indicating that the linker was not cleaved. Nevertheless, EcrFTL presented HA against rabbit erythrocytes, although it required more time to develop this activity than FTL. Thus, the HA of FTL is not strictly dependent on linker cleavage. In assays of HA inhibition by different sugars, EcrFTL presented specificity for galactose; however, it could not be purified by affinity chromatography on *A. pavonina* galactomannan, thus revealing lower sugar-binding affinity than FTL. The biomedical properties of this EcrFTL were not evaluated since the amounts obtained through this strategy were unsatisfactory and we were willing to improve them.

![**Main strategies for the production of soluble recombinant FTL in *Escherichia coli* (A) and *Pichia pastoris*(B).** Different frutalin codifying genes were cloned in *E. coli* and *P. pastoris*, which deduced amino-acid sequences share 93% of identity (Table 2 in [@B29]).](fpls-05-00390-g001){#F1}

Taking into account the low production yields previously obtained, fusion protein technology was afterward considered to improve the soluble production and purification of recombinant FTL in *E. coli*. Eight fusion tags (His~6~, Trx, GST, NusA, MBP, SUMO, H, and Fh8), included in pETM vectors (EMBL), were evaluated in small-scale screening assays for recombinant FTL solubility in four *E. coli* strains ([@B8]; **Figure [1](#F1){ref-type="fig"}**). All vectors provided a His~6~ tag for purification of the EcrFTL fusions by nickel affinity (immobilized metal ion affinity chromatography -- IMAC). The Rosetta strain (DE3) was selected for scale-up protein processing, namely purification and solubility evaluation before and after tag cleavage. The solubility enhancer partners NusA, Trx, and Fh8 tags considerably improved the soluble production of EcrFTL (in the order: NusA∼Fh8 \> Trx), being the protein soluble after their removal by TEV cleavage (Tobacco Etch Virus protease). Interestingly, the cleaved and purified EcrFTL from the Fh8 and Trx fusions presented higher amounts than that cleaved from the NusA fusion protein ([@B8]). The fusion protein strategy boosted the availability of EcrFTL by increasing its yield from μg to mg of active protein per liter of *E. coli* culture whilst simplifying the complete production and purification protocol ([@B6]). IMAC revealed to be a simpler, easier and quicker procedure than SEC or IEC for EcrFTL purification, and it also decreased EcrFTL losses during purification. Moreover, EcrFTL kept its HA when fused to this partner (our unpublished results). However, the His~6~FTL fusion (produced from vector pETM-11) was found to be a very unstable protein, precipitating at physiological pH, and thus being incompatible with cell culture conditions for evaluation of its anti-tumor activity (our unpublished results). Among the fusion partners tested, the Fh8 tag was pointed as a good option for the production of soluble EcrFTL in *E. coli* because of its advantageous low molecular weight and combined solubility enhancer and purification handle activities ([@B6]). The Fh8 tag (*Fasciola hepatica* 8-kDa antigen) has been recently ranked among the best solubility enhancer partners for recombinant protein production in *E. coli* ([@B8], [@B7]). Fh8 was also shown as a suitable fusion partner for purification of recombinant proteins in *E. coli* by HIC (hydrophobic interaction chromatography), with efficiencies comparable to those of IMAC ([@B9]). Besides improving EcrFTL solubility, the Fh8 tag increased EcrFTL stability, compared to the His~6~ tag, and it did not interfere with the HA and structure (in respect to β-sheet conformation) of EcrFTL, before and after its cleavage ([@B6]). The anti-tumor activity of these two versions of EcrFTL, the Fh8FTL and Fh8-cleaved FTL, is under evaluation.

PRODUCTION OF RECOMBINANT FRUTALIN IN *P. pastoris*
===================================================

PRODUCTION AND BIO-MOLECULAR CHARACTERIZATION
---------------------------------------------

Frutalin has highly glycosylated isoforms and the presence of the glycans may be important for its functional properties. Thus, we planned to produce FTL in a microorganism capable of performing glycosylation, namely using the strain *P. pastoris* KM71H ([@B30]; **Figure [1](#F1){ref-type="fig"}**). FTL gene (encoding a mature sequence; [@B29]) was optimized based on the codon usage of *P. pastoris* and integrated into the yeast genome *in frame* at the *C*-terminal of the *Saccharomyces* α-factor preprosequence (MFα), to direct PprFTL into the secretory pathway, and under the control of the strong methanol inducible *AOX*1 promoter. PprFTL was produced in shake-flasks and purified from supernatants by SEC yielding 18--20 mg per liter of culture.

Important differences between the molecular and biological properties of PprFTL and FTL were found ([@B30]). The reason for that was the processing of FTL in *P. pastoris*, which was different from that occurring in breadfruit. As also observed in *E. coli* ([@B29]), the FTL linker was not cleaved in *P. pastoris* (confirmed by *N*-terminal sequencing), thus suggesting that this processing can be specific for higher eukaryotes. Furthermore, the MFα secretion leader was incompletely removed, resulting in PprFTL with one Glu-Ala repeat at its *N*-terminal, decreasing its predicted PI (isoeletric point) from 8 to 5. These repeats are commonly observed in heterologous proteins secreted by *P. pastoris* using this signal sequence, and also reported for other recombinant plant lectins ([@B35]; [@B18]).

As expected, PprFTL was *N*-glycosylated by *P. pastoris*, since the corresponding protein sequence has one potential site for *N*-glycosylation (α-Asn74). Part of the secreted PprFTL undergone this post-translational modification, which led to an extension in its molecular weight of about 2.8 kDa ([@B31]). PprFTL, contrarily to FTL, did not agglutinate rabbit erythrocytes, despite also having a tetrameric structure ([@B30]). Thus, it was hypothesized that glycosylation pattern of *P. pastoris* inhibited this activity since non-glycosylated EcrFTL presented HA. In a previous work, *Pichia* glycosylation was also suggested to inhibit the HA of a fungal lectin ([@B17]). Nevertheless, it should be noted that different FTL coding sequences were cloned in *P. pastoris* and *E. coli*, and hence the HA of the resulting proteins may differ. The deduced amino-acid sequences of the frutalin codifying genes cloned in *P. pastoris* and*E. coli* have 93% of sequence identity (**Figure [1](#F1){ref-type="fig"}**). In what concerns carbohydrate-binding activity, PprFTL presented a sugar preference similar to FTL, but with less affinity. The affinity constant for the binding of PprFTL to the monosaccharide methyl-α-galactose was determined and found to be 113-fold lower than that of FTL ([@B30]). The only other gJRL so far produced in microorganisms was jacalin. Jacalin was produced in *E. coli* also as an unprocessed protein with its sugar-binding activities reduced in the same order of magnitude ([@B37]). The correct excision of the linker and consequent generation of a free glycine at the *N*-terminus of the α chain may determine gJRLs sugar-binding properties ([@B16]; [@B37]; [@B30]).

The large-scale production of PprFTL was conducted in a 1.6 L stirred tank bioreactor operating in fed-batch mode at 28°C during 4 days ([@B38]). Supplementation of the culture medium (BMMH -- buffered minimal methanol medium) with *Pichia* trace minerals (PTM) resulted in 2.5-fold higher PprFTL production (13.4 mg/l) than that achieved without supplementation (5.23 mg/l). Furthermore, bioreactor resulted in fourfold higher PprFTL production, comparing to shaker-flasks batch assays (3.3 mg/l), using the same culture medium (BMMH plus PTM) and induction conditions ([@B38]). Nevertheless, the yield of PprFTL was higher from shake-flasks induced at 15°C (18--20 mg/l), which means that lower temperatures favor PprFTL production ([@B30]). However, 20 of such flasks (each containing 50 ml of BMMH medium) are needed to obtain the same amount of PprFTL as in one fed-batch experiment. Thus, bioreactor fermentation is more advantageous for the production of PprFTL.

BIOMEDICAL PROPERTIES
---------------------

The relevance of JRLs, specifically jacalin, for cancer diagnostics and therapeutics is present in many recent works (e.g., [@B27]; [@B19]; [@B23]; [@B40]). PprFTL was evaluated in terms of its tumor biomarker and anti-tumor properties, comparatively to FTL ([@B33], [@B31]). The cancer biomarker study was performed by immunohistochemistry with human prostate tissues ([@B33]). Other plant lectins were used in the past in similar studies but with limited success (works cited in [@B33]). The binding pattern of PprFTL and FTL to the prostate tissues was distinct, presumably due to their differences in carbohydrate-binding affinity ([@B30]). FTL bound to any type of prostate cells but more strongly to the neoplasic (malignant cells) than to the hyperplasic ones (non-malignant cells). On the other hand, PprFTL was much more specific, as it just recognized malignant cells (**Figure [2](#F2){ref-type="fig"}**). A significant positive statistical correlation between the binding intensity of PprFTL and the histological diagnosis of the tissues was obtained (not observed for FTL), although PprFTL did not recognize all the malignant cases studied (30% had negative binding), and when positive, the binding was heterogeneous. However, only a small number of prostate cases were analyzed and the histochemical methodology has still room for improvement. This study indicates that PprFTL has higher potential as cancer biomarker than FTL.

![**Immunostaining pictures of a prostate cancer tissue using recombinant FTL produced in *P. pastoris* as tumor diagnostic marker.** PprFTL was able to specifically recognize carcinoma cells in middle of a benign lesion. The staining is localized in the cells cytoplasm of the carcinoma glands (brown color). (Original publisher: BioMed Central; Adapted from [@B33]).](fpls-05-00390-g002){#F2}

In *in vitro* assays, PprFTL showed a strong cytotoxic effect on HeLa cervical cancer cells proliferation, by inducing cell dead by apoptosis ([@B31]). This effect was irreversible as well as time and dose dependent (IC~50~ ∼ 100 μg/mL). Identical results were obtained for FTL in the same study ([@B31]). Thus, it seems that frutalin action in tumor cells is not exclusively dependent on its carbohydrate-binding properties. Other factors, such as protein--protein interactions, may contribute to the cellular responses, as suggested for the effect of recombinant jacalin in tumor cells ([@B36]). Recombinant jacalin showed a magnitude of anti-proliferative responses similar to native jacalin on human cancer cell lines, despite its inferior sugar-binding affinity ([@B36]). Both, PprFTL and FTL showed nuclear migration activity on HeLa cells ([@B31]), a property only reported for fungal lectins ([@B39]; [@B12]; [@B21]). Plant lectins have been described to attach to cancer cells membrane \[e.g., jacalin in A431 human epidermoid carcinoma cells ([@B36])\] or to be internalized and located in different cellular compartments \[e.g., wheat germ agglutinin, WGA, in DU-145 human prostate cancer cells ([@B14])\]. To our knowledge, our work is the first reporting nuclear migration activity on cancer cells for a lectin from plant origin ([@B31]). Studies aiming to elucidate the apoptotic mechanism triggered by PprFTL on cancer cells are now being conducted.

CONCLUSION AND PROSPECTS
========================

*Escherichia coli* and *Pichia pastoris* were found as suitable hosts for producing high amounts of recombinant FTL upon production and purification optimization. Optimization in *E. coli* significantly improved EcrFTL production, leading to high yields, but decreased protein stability. Furthermore, the processing of recombinant FTL in both microorganisms was different from that occurring in breadfruit, resulting in versions of FTL with inferior HA and carbohydrate-binding capacity. Nevertheless, PprFTL presented an anti-tumor activity identical to FTL and enhanced tumor biomarker capacity. The production strategies herein presented will extend the research on the biomedical properties of recombinant FTL.

The importance of amino-acids substitutions and post-translational modifications in gJRLs (e.g., linker cleavage, glycosylation) remains to be elucidated, and thus, future research might follow this direction. Within this scope, production and the availability of heterologous recombinant lectins is a valuable tool that can contribute to the fundamental understanding of the biological activity of the lectins. The production of the same lectin coding sequence in prokaryotic and eukaryotic hosts, the production of different lectin isoforms, and engineered/mutated versions, will provide insight into lectins functionality and shed light into its native physiological role. Furthermore, recombinant lectins with refined properties can be obtained. Finally, the fusion of enhanced lectins with functional moieties, by using recombinant DNA technology, for the development of functionalized drug delivery systems for site specific anti-tumor therapy, is anticipated.

AUTHOR CONTRIBUTIONS
====================

Carla Oliveira drafted the review and carried out most of the experimental work of recombinant FTL. José A. Teixeira participated in the development of the concept. Lucília Domingues conceived the study and helped to draft the review. All authors read and approved the final manuscript.

Conflict of Interest Statement
==============================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Carla Oliveira acknowledges support from Fundação para a Ciência e a Tecnologia (FCT), Portugal (by the fellowship SFRH/BDP/63831/2009). The authors thank the FCT GlycoCBMs Project REF. FCT PTDC/AGR-FOR/3090/2012 -- FCOMP-01-0124-FEDER-027948, the FCT Strategic Project PEst-OE/EQB/LA0023/2013, and the Project "BioInd -- Biotechnology and Bioengineering for improved Industrial and Agro-Food processes," REF. NORTE-07-0124-FEDER-000028 Co-funded by the Programa Operacional Regional do Norte (ON.2 -- O Novo Norte), QREN, FEDER.

[^1]: Edited by: *Els Jm Van Damme, Ghent University, Belgium*

[^2]: Reviewed by: *Wim Van Den Ende, Katholieke Universiteit Leuven, Belgium; Alexander D. Frey, Aalto University, Finland*

[^3]: This article was submitted to Plant Physiology, a section of the journal Frontiers in Plant Science.
